Targeting multiple pathways in childhood brain tumors with lipid nanomedicine
Lipid nanomedicine targeting multiple signaling pathways of medulloblastoma
This study is looking at a new way to treat medulloblastoma, the most common brain tumor in kids, by using special tiny particles that can help deliver medicine directly to the tumor and make it easier to fight while causing fewer side effects.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Nebraska Medical Center NIH-funded |
| Lab location | 1 site (Omaha, United States) |
| Project ID | NIH-11126868 on NIH RePORTER |
What this research studies
This research focuses on medulloblastoma, the most common brain tumor in children, by investigating how lipid nanomedicine can effectively target multiple signaling pathways involved in tumor growth and resistance to treatment. The approach involves developing dual inhibitors that can penetrate the blood-brain barrier and modulate key proteins that contribute to tumor proliferation and metastasis. By synthesizing and testing these compounds, the research aims to improve treatment efficacy and reduce side effects associated with current therapies.
Who could benefit from this research
Good fit: Ideal candidates for this research are children diagnosed with medulloblastoma who are undergoing treatment or have shown resistance to current therapies.
Not a fit: Patients with other types of brain tumors or those who are not diagnosed with medulloblastoma may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for medulloblastoma, potentially improving survival rates and quality of life for affected children.
How similar studies have performed: Previous research has shown promise in targeting similar pathways in other cancers, indicating that this approach may be effective, although it is still relatively novel in the context of medulloblastoma.
Where this research is happening
Omaha, United States
- University of Nebraska Medical Center — Omaha, United States (Active)
Researchers
- Principal investigator: Mahato, Ram I. — University of Nebraska Medical Center
- Study coordinator: Mahato, Ram I.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.